降压|我国首部一级预防指南:单片固定复方制剂协同降压、改善患者依从性

*本文仅供医学专业人士阅读和参考
降压|我国首部一级预防指南:单片固定复方制剂协同降压、改善患者依从性
文章图片


图3:氨氯地平±培哚普利联合治疗降低多项终点事件风险率
降压|我国首部一级预防指南:单片固定复方制剂协同降压、改善患者依从性
文章图片


图4:氨氯地平±培哚普利长期随访结果
此外,培哚普利/氨氯地平SPC只需一天一片,服用方便,在一项对医疗保险数据的回顾性分析[13],同样证实了培哚普利/氨氯地平SPC较自由联合治疗可显著提高依从性 。
总结
我国是高血压大国,对高血压患者进行早期、强化干预可进一步减轻我国的心血管疾病负担,对我国的卫生健康事业具有深远的意义 。首部一级预防指南参考国内外最新临床证据,进行了充分的证据检索和系统评价,其颁布和实施将为推进我国心血管病预防实践发挥积极作用 。
【降压|我国首部一级预防指南:单片固定复方制剂协同降压、改善患者依从性】参考文献:
[1] 中华医学会心血管病学分会等. 中国心血管病一级预防指南[J].中华心血管病杂志, 2020,48(12):1-39.
[2] 国家心血管病中心.中国心血管病报告2016[M1.北京:中 国大百科全书出版社,2017.
[3] ACCORD Study Group, et al. Effects of intensive blood-pressure control in type 2 diabetes mellitus. N Engl J Med. 2010 Apr 29;362(17):1575-85.
[4] SPRINT Research Group, et al. A Randomized Trial of Intensive versus Standard Blood-Pressure Control. N Engl J Med. 2015 Nov 26;373(22):2103-16.
[5] SPS3 Study Group, et al. Blood-pressure targets in patients with recent lacunar stroke: the SPS3 randomised trial. Lancet. 2013 Aug 10;382(9891):507-15.
[6] Dahl?f B, Sever P S, Poulter N R, et al. Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BP[J]. Lancet, 2005, 366(9489):895-906.
[7drochlorothiazide for hypertension in high-risk patients. N Engl J Med. 2008 Dec 4;359(23):2417-28.
[8] Bahl VK, et al. Am J Cardiovasc Drugs. 2009;9:135-142.2. Mourad JJ. J Hypertens. 2011;29 Suppl 1:S23-S28.
[9] Yuri A K, et al. Effectiveness of Fixed-Dose Perindopril/Amlodipine on Clinic, Ambulatory and Self-Monitored Blood Pressure and Blood Pressure Variability: An Open-Label, Non Comparative Study in the General Practice. High Blood Press Cardiovasc Prev 2015,22(4):417
[10] Gupta A, Mackay J, Whitehouse A, et al. Long-term mortality after blood pressure-lowering and lipid-lowering treatment in patients with hypertension in the Anglo-Scandinavian Cardiac Outcomes Trial (ASCOT) Legacy study: 16-year follow-up results of a randomised factorial trial. Lancet. 2018 Sep 29;392(10153):1127-1137.

    推荐阅读